June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Quantification of VEGF in peripheral blood as a marker of activity in diabetic retinopathy.
Author Affiliations & Notes
  • Ulises de Dios Cuadras
    Asociación para Evitar la Ceguera en México "Hospital Dr.Luis Sánchez Bulnes" IAP, Mexico, Mexico, Mexico
  • Brenda Yazmin Juarez Dominguez
    Asociación para Evitar la Ceguera en México "Hospital Dr.Luis Sánchez Bulnes" IAP, Mexico, Mexico, Mexico
  • Carlos Rafael Vargas Riaño
    Asociación para Evitar la Ceguera en México "Hospital Dr.Luis Sánchez Bulnes" IAP, Mexico, Mexico, Mexico
  • Juan Manuel Jimenez-Sierra
    Asociación para Evitar la Ceguera en México "Hospital Dr.Luis Sánchez Bulnes" IAP, Mexico, Mexico, Mexico
  • Luis F Hernandez-Zimbron
    Universidad Nacional Autónoma de Mexico, Mexico, Mexico
  • Oscar Vivanco Rojas
    Asociación para Evitar la Ceguera en México "Hospital Dr.Luis Sánchez Bulnes" IAP, Mexico, Mexico, Mexico
  • Footnotes
    Commercial Relationships   Ulises de Dios Cuadras, None; Brenda Yazmin Juarez Dominguez, None; Carlos Rafael Vargas Riaño, None; Juan Jimenez-Sierra, None; Luis F Hernandez-Zimbron, None; Oscar Vivanco Rojas, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 5027. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Ulises de Dios Cuadras, Brenda Yazmin Juarez Dominguez, Carlos Rafael Vargas Riaño, Juan Manuel Jimenez-Sierra, Luis F Hernandez-Zimbron, Oscar Vivanco Rojas; Quantification of VEGF in peripheral blood as a marker of activity in diabetic retinopathy.. Invest. Ophthalmol. Vis. Sci. 2017;58(8):5027.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Diabetic retinopathy (DR) is one of the main causes of blindness worldwide. There are several therapeutic options for this condition, but there is a large group of patients that are not treated until they reach the latest stages of the disease.
The vascular endothelial growth factor (VEGF) has been related with diabetic retinopathy and the purpose of this prospective, observational descriptive clinical study is to correlate the serum levels of VEGF as a risk factor for progression of diabetic retinopathy.

Methods : We recruited 90 patients classified as follows: 30 patients without diabetes, 30 patients without active progression of DR and 30 patients with active progression of DR. This classification was corroborated by biomicroscopy or fluorescein angiography in selected cases.
We quantified VEGF levels by western blot test in serum samples of each patient.

Results : We could demonstrate that higher levels of serum VEGF were found on patients with active progression of diabetic retinopathy with statistical significance compared to the group of DR without progression (p 0.001) a.d the group without diabetes (p 0.002).

Conclusions : Serum VEGF quantification could be used as a marker to predict which patients are in higher risk of progression of diabetic retinopathy. Therefor it could be a useful instrument to determine which patients should be treated on earlier stages of the disease, with the intention of avoiding complications of DR and improve their outcome.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×